Results from the Phase 3 DISCOVER-2 trial evaluating guselkumab for active psoriatic arthritis in biologic-naive patients were published on January 1, 2020. This pivotal study assessed the efficacy and safety of guselkumab administered subcutaneously in this patient population.
Background
Guselkumab, also known by its brand name Tremfya, is a medication developed for the treatment of inflammatory conditions. This particular study focused on its use in patients diagnosed with active psoriatic arthritis, a chronic inflammatory disease that affects both the joints and the skin. The DISCOVER-2 trial specifically targeted biologic-naive patients, meaning individuals who had not previously received biologic disease-modifying antirheumatic drugs (DMARDs) for their condition.
Trial design
The published article details the DISCOVER-2 study, which was a Phase 3, double-blind, randomised, and placebo-controlled trial. It investigated guselkumab in participants with active psoriatic arthritis who were biologic-naive. The study's primary objective, as indicated by its summary, was to evaluate the efficacy and safety of guselkumab when administered subcutaneously. The design included a comparison against a placebo arm to rigorously assess the drug's specific effects on the disease.
What this means
The publication of the DISCOVER-2 trial results makes important data available for the medical community regarding guselkumab as a potential treatment option for active psoriatic arthritis in biologic-naive patients. While specific efficacy and safety outcomes are not detailed in the provided information, the completion and publication of a Phase 3, placebo-controlled study suggest that comprehensive data on the drug's performance in this population is now accessible for clinical review and decision-making. These findings contribute to the understanding of treatment strategies for psoriatic arthritis.
Source
The information regarding the DISCOVER-2 trial was published on January 1, 2020, in The Lancet, and indexed by PubMed. The source document, titled "Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial," can be accessed via pubmed.ncbi.nlm.nih.gov.